Alpha-L-Fucosidase Has Diagnostic Value in Prostate Cancer With “Gray-Zone PSA” and Inhibits Cancer Progression via Regulating Glycosylation

BackgroundThis study aimed to explore the diagnostic value of alpha-l-fucosidase (AFU) in prostate cancer (PCa) patients with “gray-zone PSA” and to investigate the correlation between AFU expression and clinicopathological characteristics of PCa patients.MethodsThe level of AFU and other necessary...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cong Zhang, Jikai Liu, Fan Chao, Shiyu Wang, Dawei Li, Dunsheng Han, Zhonghua Xu, Guoxiong Xu, Gang Chen
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	prostate cancer AFU diagnosis tumor progression progression-free interval Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/55d1532a0f9041379a06f42beb7c748c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:55d1532a0f9041379a06f42beb7c748c
record_format	dspace
spelling	oai:doaj.org-article:55d1532a0f9041379a06f42beb7c748c2021-11-22T04:57:50ZAlpha-L-Fucosidase Has Diagnostic Value in Prostate Cancer With “Gray-Zone PSA” and Inhibits Cancer Progression via Regulating Glycosylation2234-943X10.3389/fonc.2021.742354https://doaj.org/article/55d1532a0f9041379a06f42beb7c748c2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.742354/fullhttps://doaj.org/toc/2234-943XBackgroundThis study aimed to explore the diagnostic value of alpha-l-fucosidase (AFU) in prostate cancer (PCa) patients with “gray-zone PSA” and to investigate the correlation between AFU expression and clinicopathological characteristics of PCa patients.MethodsThe level of AFU and other necessary clinicopathological variables of patients were retrieved from electronic medical records. The transcriptome profiling and clinical information of PCa patients were obtained from The Cancer Genome Atlas (TCGA) database. The protein level of AFU in tissue was assessed by immunohistochemistry (IHC). All the data were processed by appropriate analysis methods. The p-value of <0.05 was considered statistically significant.ResultsAFU showed ideal diagnostic value for PCa with prostate-specific antigen (PSA) levels ranging from 4 to 10 ng/ml, and its optimal cutoffs were 19.5 U/L. Beyond this, low AFU expression was associated with high pathological grade, T stage and N stage, more postoperative residual tumors, and poor primary therapy outcome, as well as shorter progression-free interval. The Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis illustrated that FUCA1/FUCA2 exerted tumor-suppressive function by regulating the glycosylation.ConclusionsAFU (<19.5 U/L) could effectively distinguish the PCa from the patients with “gray-zone PSA”, and low expression of AFU was an independent unfavorable predictor for the clinicopathological characteristics of PCa patients.Cong ZhangJikai LiuFan ChaoShiyu WangDawei LiDunsheng HanZhonghua XuGuoxiong XuGang ChenFrontiers Media S.A.articleprostate cancerAFUdiagnosistumor progressionprogression-free intervalNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	prostate cancer AFU diagnosis tumor progression progression-free interval Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	prostate cancer AFU diagnosis tumor progression progression-free interval Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Cong Zhang Jikai Liu Fan Chao Shiyu Wang Dawei Li Dunsheng Han Zhonghua Xu Guoxiong Xu Gang Chen Alpha-L-Fucosidase Has Diagnostic Value in Prostate Cancer With “Gray-Zone PSA” and Inhibits Cancer Progression via Regulating Glycosylation
description	BackgroundThis study aimed to explore the diagnostic value of alpha-l-fucosidase (AFU) in prostate cancer (PCa) patients with “gray-zone PSA” and to investigate the correlation between AFU expression and clinicopathological characteristics of PCa patients.MethodsThe level of AFU and other necessary clinicopathological variables of patients were retrieved from electronic medical records. The transcriptome profiling and clinical information of PCa patients were obtained from The Cancer Genome Atlas (TCGA) database. The protein level of AFU in tissue was assessed by immunohistochemistry (IHC). All the data were processed by appropriate analysis methods. The p-value of <0.05 was considered statistically significant.ResultsAFU showed ideal diagnostic value for PCa with prostate-specific antigen (PSA) levels ranging from 4 to 10 ng/ml, and its optimal cutoffs were 19.5 U/L. Beyond this, low AFU expression was associated with high pathological grade, T stage and N stage, more postoperative residual tumors, and poor primary therapy outcome, as well as shorter progression-free interval. The Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis illustrated that FUCA1/FUCA2 exerted tumor-suppressive function by regulating the glycosylation.ConclusionsAFU (<19.5 U/L) could effectively distinguish the PCa from the patients with “gray-zone PSA”, and low expression of AFU was an independent unfavorable predictor for the clinicopathological characteristics of PCa patients.
format	article
author	Cong Zhang Jikai Liu Fan Chao Shiyu Wang Dawei Li Dunsheng Han Zhonghua Xu Guoxiong Xu Gang Chen
author_facet	Cong Zhang Jikai Liu Fan Chao Shiyu Wang Dawei Li Dunsheng Han Zhonghua Xu Guoxiong Xu Gang Chen
author_sort	Cong Zhang
title	Alpha-L-Fucosidase Has Diagnostic Value in Prostate Cancer With “Gray-Zone PSA” and Inhibits Cancer Progression via Regulating Glycosylation
title_short	Alpha-L-Fucosidase Has Diagnostic Value in Prostate Cancer With “Gray-Zone PSA” and Inhibits Cancer Progression via Regulating Glycosylation
title_full	Alpha-L-Fucosidase Has Diagnostic Value in Prostate Cancer With “Gray-Zone PSA” and Inhibits Cancer Progression via Regulating Glycosylation
title_fullStr	Alpha-L-Fucosidase Has Diagnostic Value in Prostate Cancer With “Gray-Zone PSA” and Inhibits Cancer Progression via Regulating Glycosylation
title_full_unstemmed	Alpha-L-Fucosidase Has Diagnostic Value in Prostate Cancer With “Gray-Zone PSA” and Inhibits Cancer Progression via Regulating Glycosylation
title_sort	alpha-l-fucosidase has diagnostic value in prostate cancer with “gray-zone psa” and inhibits cancer progression via regulating glycosylation
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/55d1532a0f9041379a06f42beb7c748c
work_keys_str_mv	AT congzhang alphalfucosidasehasdiagnosticvalueinprostatecancerwithgrayzonepsaandinhibitscancerprogressionviaregulatingglycosylation AT jikailiu alphalfucosidasehasdiagnosticvalueinprostatecancerwithgrayzonepsaandinhibitscancerprogressionviaregulatingglycosylation AT fanchao alphalfucosidasehasdiagnosticvalueinprostatecancerwithgrayzonepsaandinhibitscancerprogressionviaregulatingglycosylation AT shiyuwang alphalfucosidasehasdiagnosticvalueinprostatecancerwithgrayzonepsaandinhibitscancerprogressionviaregulatingglycosylation AT daweili alphalfucosidasehasdiagnosticvalueinprostatecancerwithgrayzonepsaandinhibitscancerprogressionviaregulatingglycosylation AT dunshenghan alphalfucosidasehasdiagnosticvalueinprostatecancerwithgrayzonepsaandinhibitscancerprogressionviaregulatingglycosylation AT zhonghuaxu alphalfucosidasehasdiagnosticvalueinprostatecancerwithgrayzonepsaandinhibitscancerprogressionviaregulatingglycosylation AT guoxiongxu alphalfucosidasehasdiagnosticvalueinprostatecancerwithgrayzonepsaandinhibitscancerprogressionviaregulatingglycosylation AT gangchen alphalfucosidasehasdiagnosticvalueinprostatecancerwithgrayzonepsaandinhibitscancerprogressionviaregulatingglycosylation
_version_	1718418160262053888

Alpha-L-Fucosidase Has Diagnostic Value in Prostate Cancer With “Gray-Zone PSA” and Inhibits Cancer Progression via Regulating Glycosylation

Ejemplares similares